What's new in 2009 in prostate cancer: Highlights from ASTRO, EAU, ASCO and AUA meetings;Les nouveautés 2009 sur le cancer de la prostate: Les points forts de l'ASTRO, l'EAU, l'ASCO et l'AUA

Progres en Urologie

Volumn 20, Issue SUPPL.1, 2010, Pages 61-67

  Salomon, L ^a   Peyromaure, M ^b   Mongiat Artus, P ^c   Roset, F ^m   Gachignard, N ^d   Bastide, C ^e   Richaud, P ^f   Beuzeboc, P ^g   Cornud, F ^h   Molinie V ⁱ   Soulie M ^j   El Fegoun, A Benchikh ^k,l  

^a HENRI MONDOR HOSPITAL   (France)

^b Hôpital Cochin ^*  (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL NORD   (France)

^f INSTITUT BERGONIÉ   (France)

^g INSTITUT CURIE   (France)

^h Centre d'Imagerie Médicale   (France)

ⁱ SAINT JOSEPH HOSPITAL   (France)

^j CHU RANGUEIL   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l BICHAT HOSPITAL   (France)

^m NONE

more..

Author keywords

Androgen deprivation therapy; Intermittent treatment; Prostate cancer; Radiation therapy; Screening

Indexed keywords

ARTICLE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; ORGANIZATION; PROSTATE TUMOR;

COMBINED MODALITY THERAPY; CONGRESSES AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 77957373838     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Andriole G, Bostwick D, Brawle O, Gomella L, Marberger M, Montorsi F, et al. Further analyses from the REDUCE prostate cancer risk reduction trial. AUA 2009:abstract LBA1.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
3. Andriole GL, Crawford ED, Grubb RL, 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostatecancer screening trial. N Engl J Med 2009;360:1310-9.
4. Roobol MJ, Schröder FH, Andriole GL, Fleshner NE. Defining men at increased risk of developing prostate cancer: evidence from a population-based screening cohort. J Urol 2009;181:747. Abstract 2063.
5. Vickers AJ, Cronin AM, Manjer J, Dahlin A, Bjartell A, Scardino PT, et al. Prostate specific antigen level at age 60 and death from prostate cancer. J Urol 2009;181:59. Abstract 163.
6. de la Taille A, Irani J, de Reijke TM, Haese A. Can prostate cancer gene 3 (PCA3) predict initial biopsy outcome? J Urol 2009;181:655. Abstract 1816.
7. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Schalken JA, Cornel EB. Detection of TMPRSS2-ERG fusion transcripts and PCA3 in urinary sediments may improve diagnosis of prostate cancer. EAU Meeting, Milan 2009, Abstract 279.
8. Groskopf J, Miick S, Kwon GY, Wixom C, Nigwekar P, Tadros Y, et al. Direct detection of TMPRSS2: ETS gene fusion mRNAs in prostatectomy tissue: prevalence and correlation with pathologic features. EAU Meeting, Milan 2009. Abstract 283.
9. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
10. Stephenson AJ, Klein EA, Kattan MW, Han M, Partin AW, Walsh PC, et al. Predicting the long-term risk of prostate cancerspecific mortality after radical prostatectomy. J Clin Oncol 2009;27:abstract 5007.
11. Antonarakis ES, Trock BJ, Feng Z, Humphrey EB, Carducci MA, Partin AW. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after radical prostatectomy: 25-year follow-up. J Clin Oncol 2009;27: abstract 5008.
12. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, et al. Gleason Score and Lethal Prostate Cancer: Does 3+4=4+3? J Clin Oncol 2009;27:21.
13. Nelson JB. The evolving presentation and natural history of prostate cancer: who should not be treated? J Clin Oncol 2009;27:15s.
14. Glode LM, Tangen CM, Hussain MH, Wood DP, Swanson GP, Quinn DI, et al. Southwest Oncology Group S9921: Prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. J Clin Oncol 2009;27: abstract 5009.
15. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301-8.
16. Mottet NA, Goussard M, Loulidi S, Wolff JM. Intermittent versus continuous maximal androgen blockade in metastatic (D2) prostate cancer patients. A randomized trial. J Urol 2009;181:233. Abstract 645.
17. Lin DD, Marks LS, Morton RA, Rodriguez D. Positive fracture réduction trial of Toremifene 80 mg in men on ADT demonstrates significant fracture risk in untreated placebo group. J Urol 2009;181:229. Abstract 639.
18. Veverka KA, Malkowicz B, Smith M, Morton RA, Steiner MS, et al. The effect of Toremifene citrate on BMD in men on ADT: A phase III clinical trial. J Clin Oncol 2009;27:abstract 5055.
19. Saad F, Smith FM, Egerdie B, Tammela TL, Feldman RA, Heracek J, et al. Denosumab for prevention of fractures in men receiving androgen deprivation therapy (ADT) for prostate cancer (PC). J Clin Oncol 2009;27:abstract 5056.
20. Scher HI, Beer TM, Higano CS, Logothetis C, Anand A, Hirmand M, et al. Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC). J Clin Oncol 2009;27:abstract 151.
21. Reid AH, Attard G, Danila D, Ryan CJ, Thompson E, Kheoh T, et al. A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts). J Clin Oncol 2009;27:abstract 5047.